These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 14570885)

  • 1. Structure-activity relationship of synthetic toll-like receptor 4 agonists.
    Stöver AG; Da Silva Correia J; Evans JT; Cluff CW; Elliott MW; Jeffery EW; Johnson DA; Lacy MJ; Baldridge JR; Probst P; Ulevitch RJ; Persing DH; Hershberg RM
    J Biol Chem; 2004 Feb; 279(6):4440-9. PubMed ID: 14570885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taking toll: lipid A mimetics as adjuvants and immunomodulators.
    Persing DH; Coler RN; Lacy MJ; Johnson DA; Baldridge JR; Hershberg RM; Reed SG
    Trends Microbiol; 2002; 10(10 Suppl):S32-7. PubMed ID: 12377566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents.
    Baldridge JR; McGowan P; Evans JT; Cluff C; Mossman S; Johnson D; Persing D
    Expert Opin Biol Ther; 2004 Jul; 4(7):1129-38. PubMed ID: 15268679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge.
    Cluff CW; Baldridge JR; Stöver AG; Evans JT; Johnson DA; Lacy MJ; Clawson VG; Yorgensen VM; Johnson CL; Livesay MT; Hershberg RM; Persing DH
    Infect Immun; 2005 May; 73(5):3044-52. PubMed ID: 15845512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR4 agonists as immunomodulatory agents.
    Alderson MR; McGowan P; Baldridge JR; Probst P
    J Endotoxin Res; 2006; 12(5):313-9. PubMed ID: 17059695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.
    Hawkins LD; Ishizaka ST; McGuinness P; Zhang H; Gavin W; DeCosta B; Meng Z; Yang H; Mullarkey M; Young DW; Yang H; Rossignol DP; Nault A; Rose J; Przetak M; Chow JC; Gusovsky F
    J Pharmacol Exp Ther; 2002 Feb; 300(2):655-61. PubMed ID: 11805229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
    Mullarkey M; Rose JR; Bristol J; Kawata T; Kimura A; Kobayashi S; Przetak M; Chow J; Gusovsky F; Christ WJ; Rossignol DP
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1093-102. PubMed ID: 12604686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrophages exposed continuously to lipopolysaccharide and other agonists that act via toll-like receptors exhibit a sustained and additive activation state.
    Hume DA; Underhill DM; Sweet MJ; Ozinsky AO; Liew FY; Aderem A
    BMC Immunol; 2001; 2():11. PubMed ID: 11686851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages.
    Sweet MJ; Campbell CC; Sester DP; Xu D; McDonald RC; Stacey KJ; Hume DA; Liew FY
    J Immunol; 2002 Jan; 168(1):392-9. PubMed ID: 11751985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture.
    Uehara A; Yang S; Fujimoto Y; Fukase K; Kusumoto S; Shibata K; Sugawara S; Takada H
    Cell Microbiol; 2005 Jan; 7(1):53-61. PubMed ID: 15617523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling by toll-like receptor 2 and 4 agonists results in differential gene expression in murine macrophages.
    Hirschfeld M; Weis JJ; Toshchakov V; Salkowski CA; Cody MJ; Ward DC; Qureshi N; Michalek SM; Vogel SN
    Infect Immun; 2001 Mar; 69(3):1477-82. PubMed ID: 11179315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-like receptor (TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells.
    Parker LC; Whyte MK; Vogel SN; Dower SK; Sabroe I
    J Immunol; 2004 Apr; 172(8):4977-86. PubMed ID: 15067079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics.
    Johnson DA
    Curr Top Med Chem; 2008; 8(2):64-79. PubMed ID: 18289078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages.
    Schilling D; Thomas K; Nixdorff K; Vogel SN; Fenton MJ
    J Immunol; 2002 Nov; 169(10):5874-80. PubMed ID: 12421970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses.
    Means TK; Jones BW; Schromm AB; Shurtleff BA; Smith JA; Keane J; Golenbock DT; Vogel SN; Fenton MJ
    J Immunol; 2001 Mar; 166(6):4074-82. PubMed ID: 11238656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Toll-like receptor agonists induce distinct macrophage responses.
    Jones BW; Means TK; Heldwein KA; Keen MA; Hill PJ; Belisle JT; Fenton MJ
    J Leukoc Biol; 2001 Jun; 69(6):1036-44. PubMed ID: 11404392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors.
    Pinhal-Enfield G; Ramanathan M; Hasko G; Vogel SN; Salzman AL; Boons GJ; Leibovich SJ
    Am J Pathol; 2003 Aug; 163(2):711-21. PubMed ID: 12875990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities.
    Johnson DA; Keegan DS; Sowell CG; Livesay MT; Johnson CL; Taubner LM; Harris A; Myers KR; Thompson JD; Gustafson GL; Rhodes MJ; Ulrich JT; Ward JR; Yorgensen YM; Cantrell JL; Brookshire VG
    J Med Chem; 1999 Nov; 42(22):4640-9. PubMed ID: 10579826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SDZ MRL 953, a lipid A analog as selective cytokine inducer.
    Stern A; Engelhardt R; Foster C; Golenbock D; Hildebrandt J; Landmann R; Mayer P; Stütz P
    Prog Clin Biol Res; 1995; 392():549-65. PubMed ID: 8524963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.